Chiglitazar

Metformin

Shengjing HospitalPhase 2/3Active

B

61/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 46/ 100
Competitive Position: 95/ 100

Competitive context

5 Active assets in the Metformin cohort.

Asset / Sponsor	Phase	Rating
Letrozole Shanghai 10th People's Hospital	Phase 4	BBB
Metformin RenJi Hospital	Phase 4	BBB
UMBELLATINE Tianjin Anding Hospital	Phase 4	BB
INSULIN SUSP ISOPHANE RECOMBINANT HUMAN University Hospital, Strasbourg, France	Phase 2	CCC
Semaglutide RenJi Hospital	N/A	D
Liraglutide RenJi Hospital	N/A	D

Same molecule, other indications

Chiglitazar is also rated in:

polycystic ovary syndromeDormant

BB

Indicative ·

65 / 100

ChiglitazarDormant

B

Indicative ·

61 / 100

metabolic dysfunction-associated steatohepatitisDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.